ARTICLE | Market Access
Market access and indication expansion will gate Cobenfy’s ability to help fill the pharma’s major revenue holes
By Selina Koch, Executive Editor
September 27, 2024 1:13 AM UTC
It could be the middle of next year before BMS’s launch of newly approved schizophrenia therapy Cobenfy meaningfully accelerates, after which the pharma’s plan to maximize the product’s blockbuster potential will hinge on data in additional indications.
FDA’s approval on Thursday of first-in-class therapy Cobenfy, formerly KarXT, gives patients a treatment option that works differently than all the antipsychotics that came before it. The product, which Bristol Myers Squibb Co. (NYSE:BMY) will launch late next month, is a combination of xanomeline and trospium that results in M1/M4 agonism in the CNS. Virtually all other antipsychotic drugs work through effects on dopamine and serotonin receptors…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/653680/bms-s-new-schizophrenia-drug-has-big-potential-but-won-t-be-an-overnight-success